HomeAI · summaries
Storia in 7 fonti
FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients - Sanofi (NASDAQ:SNY)
FDA grants accelerated approval to Sanofi Tzield for children with newly diagnosed stage 3 type 1 diabetes, backed by Phase 3 data.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US
Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US
- ·
thehindubusinessline.com
US FDA approves expanded use of Sanofi's type 1 diabetes drug
The FDA approves Sanofi’s Tzield for type 1 diabetes, now available for children aged 8-17 recently diagnosed with stage 3.
